GDF15 and non-small cell lung carcinoma: To our knowledge, this is the first study to demonstrate whether GDF15 can predict the efficacy of PD-1/PD-L1 inhibitors and identify the association between circulating GDF15 levels and immune cell populations of PBMCs in patients with advanced NSCLC.